Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Br J Cancer. 2011 Sep 27;105(7):989-95. doi: 10.1038/bjc.2011.346. Epub 2011 Sep 6.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein expressed in several solid cancers. Our purpose was to study its role in serous ovarian cancer patients, and the association to clinicopathological variables and molecular markers.
We collected retrospectively 562 consecutive serous ovarian cancer patients treated at the Helsinki University Central Hospital. We stained tumour tissue microarrays for CIP2A by immunohistochemistry and constructed survival curves according to the Kaplan-Meier method. Associations to clinicopathological and molecular markers were assessed by the χ(2)-test.
We found strong cytoplasmic CIP2A immunoreactivity in 212 (40.4%) specimens, weak positivity in 222 (42.4%) specimens, and negative in 90 (17.2%). Immunopositive CIP2A expression was associated with high grade (P<0.0001), advanced stage (P=0.0005), and aneuploidy (P=0.001, χ(2)-test). Cancerous inhibitor of protein phosphatase 2A overexpression was also associated with EGFR protein expression (P=0.006) and EGFR amplification (P=0.043). Strong cytoplasmic CIP2A immunopositivity predicted poor outcome in ovarian cancer patients (P<0.0001, log-rank test).
Our results show that CIP2A associates with reduced survival and parameters associated with high grade in ovarian cancer patients, and may thus be one of the factors that identify aggressive subtype (type II) of this disease.
癌性蛋白磷酸酶 2A 抑制剂（CIP2A）是一种在几种实体癌中表达的癌蛋白。我们的目的是研究其在浆液性卵巢癌患者中的作用，以及与临床病理变量和分子标志物的关联。
我们回顾性收集了在赫尔辛基大学中心医院治疗的 562 例连续的浆液性卵巢癌患者。我们通过免疫组织化学方法对肿瘤组织微阵列进行 CIP2A 染色，并根据 Kaplan-Meier 方法构建生存曲线。通过 χ(2)-检验评估与临床病理和分子标志物的关联。
我们发现 212 例（40.4%）标本中有强烈的细胞质 CIP2A 免疫反应性，222 例（42.4%）标本中有弱阳性，90 例（17.2%）标本为阴性。免疫阳性 CIP2A 表达与高分级（P<0.0001）、晚期（P=0.0005）和非整倍体（P=0.001，χ(2)-检验）相关。癌性蛋白磷酸酶 2A 过表达还与 EGFR 蛋白表达（P=0.006）和 EGFR 扩增（P=0.043）相关。强烈的细胞质 CIP2A 免疫阳性预测卵巢癌患者预后不良（P<0.0001，对数秩检验）。
我们的结果表明，CIP2A 与卵巢癌患者的生存时间缩短和高级别参数相关，因此可能是识别该疾病侵袭性亚型（II 型）的因素之一。
